当前位置: 首页 >> 检索结果
共有 145088 条符合本次的查询结果, 用时 6.4398205 秒

201. Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

作者: Graham S Cooke.;Le Manh Hung.;Barnaby Flower.;Leanne McCabe.;Vu Thi Kim Hang.;Vo Thi Thu.;Dang Trong Thuan.;Nguyen Thanh Dung.;Le Thanh Phuong.;Dao Bach Khoa.;Nguyen Thi Chau An.;Pham Ngoc Thach.;Vu Thi Thu Huong.;Dang Thi Bich.;Nguyen Kim Tuyen.;M Azim Ansari.;Chau Le Ngoc.;Vo Minh Quang.;Nguyen Thi Ngoc Phuong.;Le Thi Thao.;Nguyen Bao Tran.;Evelyne Kestelyn.;Cherry Kingsley.;Rogier Van Doorn.;Motiur Rahman.;Sarah L Pett.;Guy E Thwaites.;Eleanor Barnes.;Jeremy N Day.;Nguyen Van Vinh Chau.;A Sarah Walker.
来源: Lancet. 2025年405卷10491期1769-1780页
WHO recommends treating hepatitis C infection with one of three antiviral combinations for 8-12 weeks. No randomised trials have compared these regimens, and high cure rates might be achievable with shorter durations of therapy. We aimed to compare sofosbuvir-daclatasvir with sofosbuvir-velpatasvir, and to evaluate potential novel treatment strategies.

203. The UK Supreme Court's ruling and the rights of transgender people.

作者: Joe Herbert.
来源: Lancet. 2025年405卷10491期1735页

204. The regulatory rollercoaster continues-EMA refuses donanemab.

作者: Bart De Strooper.;Christian Haass.;John Hardy.;Henrik Zetterberg.
来源: Lancet. 2025年405卷10492期1810-1812页

205. The Global North is increasingly unsafe for global health meetings.

作者: Shashika Bandara.;Nhial Deng.;Madhukar Pai.
来源: Lancet. 2025年405卷10491期1728-1730页

206. The death of Pope Francis and his global health legacy.

作者: Howard Lopes Ribeiro.
来源: Lancet. 2025年405卷10491期1735-1736页

207. Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.

作者: Jason Gardosi.;Lauren Jade Ewington.;Katie Booth.;Debra Bick.;George Bouliotis.;Emily Butler.;Sanjeev Deshpande.;Hanna Ellson.;Joanne Fisher.;Adam Gornall.;Ranjit Lall.;Hema Mistry.;Seyran Naghdi.;Stavros Petrou.;Anne-Marie Slowther.;Sara Wood.;Martin Underwood.;Siobhan Quenby.
来源: Lancet. 2025年405卷10491期1743-1756页
The benefits and harms of early induction of labour to reduce shoulder dystocia in fetuses suspected to be large for gestational age (LGA) are uncertain. We aimed to investigate whether early induction of labour is associated with a reduced risk of shoulder dystocia compared with standard care.

208. The challenge of shoulder dystocia prevention and the Big Baby trial.

作者: Christina M Scifres.;Erin M Cleary.
来源: Lancet. 2025年405卷10491期1718-1719页

209. Gastric cancer.

作者: Raghav Sundar.;Izuma Nakayama.;Sheraz R Markar.;Kohei Shitara.;Hanneke W M van Laarhoven.;Yelena Y Janjigian.;Elizabeth C Smyth.
来源: Lancet. 2025年405卷10494期2087-2102页
Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than 650 000 deaths. Epidemiologically, gastric cancer shows substantial geographical variation in incidence, with higher rates in Asia, South America, and eastern Europe, and a rapid increase in early-onset cases among people younger than 50 years. Key risk factors for gastric cancer include Helicobacter pylori infection, diet, obesity, smoking, and genetic predisposition. Early detection through comprehensive diagnostic procedures is crucial for optimising treatment outcomes. Standard treatment approaches for locally advanced gastric cancer include surgical resection, particularly D2 lymphadenectomy, complemented by chemotherapy and radiotherapy. There is increasing implementation of minimally invasive surgical techniques for operable disease and integration of immune checkpoint inhibitors and targeted therapies for advanced stages. Emerging therapies, such as novel targeted treatments and next-generation immunotherapies, show promise in improving survival and quality of life. Future directions in the management of gastric cancer focus on precision medicine, continued advancement in immunotherapy, novel early detection methods, and a multidisciplinary approach to care. These strategies aim to enhance the overall effectiveness of treatment and prognosis worldwide.

210. From disappointment to despair: USAID cuts to Myanmar's HIV services.

作者: Chengshi Shiu.;Jennifer Ho.;Myo Nyein Aung.;Wei-Ti Chen.
来源: Lancet. 2025年405卷10491期1737页

211. Can Somalia avert a food security catastrophe?

作者: Safayet Jamil.;Masoud Mohammadnezhad.;Faisal Muhammad.
来源: Lancet. 2025年405卷10492期1814页

214. Iscalimab 600 mg: justified or excessive?

作者: Yi-Yu Ho.;Hong-Chun Lin.;Chien-Min Lien.;Ming-Jen Wang.;Ching-Mao Chang.
来源: Lancet. 2025年405卷10489期1578页

215. Iscalimab 600 mg: justified or excessive? - Authors' reply.

作者: Benjamin A Fisher.;Xavier Mariette.;Wolfgang Hueber.
来源: Lancet. 2025年405卷10489期1578-1579页

216. Health service crisis in Lebanon: Hezbollah is the problem.

作者: Leslie Turnberg.;Joel Zivot.;Adam Cutler.
来源: Lancet. 2025年405卷10489期1577页

217. Gene therapy: who should decide the Deaf community's future.

作者: Tom Lichy.;Graham H Turner.;Yolande Dennis.;Anna Middleton.
来源: Lancet. 2025年405卷10489期1577-1578页

218. Towards trust and equity: Syria's health system reform.

作者: Imad Zoukar.;Mervat Muad.
来源: Lancet. 2025年405卷10489期1576-1577页

219. Rebuilding Syria's mental health system after decades of war.

作者: Darya Rostam Ahmed.;Sujita Kumar Kar.;Reinhard Heun.;Munawar Hraib.;Cyrine Ali Deeb.
来源: Lancet. 2025年405卷10489期1575页

220. Resilience amid ruins: the silent screams and steadfast spirit of Syria.

作者: Hamdah Hanifa.
来源: Lancet. 2025年405卷10489期1575-1576页
共有 145088 条符合本次的查询结果, 用时 6.4398205 秒